Hi [[ session.user.profile.firstName ]]

How to make digital work in medtech

The rise of mobile devices and apps, not to mention the involvement of non-medical technology players, is creating a wave of irrevocable digital change for medtech.
It’s transforming how the sector reaches and engages with its stakeholders and customers, and in doing so provides vital opportunities to reshape a company’s commercial model.
But although the sector can lay claim to some key success stories with digital technology, there remain a number of roadblocks impeding real digital progress for medtech.

In this webinar we will discuss key digital lessons for medtech from other healthcare sectors, steps to take for a successful digital transformation and how to ensure ROI from digital technology.
The free webinar will also see our expert panel:
•Explore the practical impacts of the new medtech business model
•Re-think the customer experience for payers and HCPs
•Learn how digital technology enables you to deliver more customer value – while powering commercial success
•Find out how virtual engagement technologies can make it happen
•See best practices and use cases from your peers
Recorded Jun 21 2018 71 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Bryn Davies (Critical Insights), Lars U. Diemer (Agnitio), Markus Ott (Ascensia), Jerome d'Astros (Edwards Lifesciences)
Presentation preview: How to make digital work in medtech

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • The Science of Healthcare Congresses Dec 3 2019 3:00 pm UTC 75 mins
    Eva Thalmann, Johnson & Johnson, Jean-Yves Douillard, ESMO, Katie Koziol and Andrew Moore, Ashfield Meetings & Events
    Research from Ashfield Meetings & Events clearly demonstrates that face-to-face meetings and events form a major part of continuing medical education (CME). National and international congresses have been identified as the primary event to attend by HCPs.

    But what makes congresses such a valuable education channel for time-restricted physicians? This pharmaphorum webinar, in association with Ashfield Meetings & Events, will dive into a unique study of HCP educational and behavioural preferences towards attendance at medical congresses.

    Ashfield Meetings & Events’ The Science of Healthcare Congresses study, involved over 200 HCPs, drawn from a range of therapy areas, from both Europe and the US to ask what really matters to them and share some intriguing insights.

    These encompassed how HCPs value this type of activity, how they apportion their time on-site and engage with the healthcare industry, and how they evaluate a congress once its doors have closed for another year.

    Join our expert panel on Monday 18th November to find out more on:

    • Why physicians attend congresses
    • How to ensure medical education provides value to attendees
    • How pharma can enhance industry symposia

    In addition, our panel will also share the results of an ongoing association and multi-pharmaceutical company research project, designed to standardise and benchmark the evaluation process of all congress medical education activities.
  • How to apply global brand strategies to every customer interaction Nov 28 2019 1:00 pm UTC 75 mins
    Massimiliano Siciliano, Grunenthal, Kasper Jerlang, LEO Pharma, Alejandra Betancourt, Anthill Agency, Dom Tyer, pharmaphorum
    Pharmaceutical companies spend a huge amount of time and resources on creating valuable brand strategies, but when they come to life there’s often a disconnect.

    Strategy and execution can easily drift apart when tactics come to life, making it harder for them to drive business and deliver on the long-term action plans to engage with healthcare professionals.

    This is as true for eDetailing or closed-loop marketing initiatives as it is for multichannel marketing strategies that encompass the latest chatbot technology or innovative digital content platforms.

    To remedy this, those working in pharma on multichannel marketing, brand planning and digital need to apply the human factor to their global brand strategies to achieve the kind of tactics that deliver on strategic goals.


    Join Anthill on Thursday 28th November from 13:00 GMT / 14:00 CET for a live expert panel discussion on multichannel marketing, brand planning and how to apply global brand strategies in pharma to every customer interaction for greater HCP reach and return-on-investment.

    In addition to looking at brand planning across pharma, common frustrations for the industry and whether or not brand planning is set up to deliver good multichannel marketing, the webinar will also cover:

    • The most common challenges in the brand planning process
    • How to build executional and strategic understanding across an entire brand plan
    • How to activate your existing channels and create the best channel mix for customers
    • How insight-based multichannel marketing can drive strategy and build new insights for the future

    The pharmaceutical industry has been making great progress in its digital transformation, but boundaries are there to be pushed if companies want to continue to innovate their marketing practices and processes.
  • Cost & Management of Oncology Combination Regimens Oct 30 2019 2:00 pm UTC 90 mins
    Marcia Palmer, Allen W. Becker, Anthony Chiefari, Howard Deutsch, Nicolle Hamilton, ZS Associates
    Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies).

    Payers are in a difficult spot regarding the cost and management of these regimens. Traditional utilization management tools are still difficult to apply in oncology, given no payer wants to be on the front page of a major newspaper for denying treatment. Pathways have not held up to their promise for containing cost.

    Personalized medicine approaches such as biomarkers serve an important role in targeting therapy to the most appropriate patients, thereby reigning in cost. However, there are limitations in the breadth and utility of these tools. For example, PD-1/PDL-1 drugs have shown conflicting outcomes associated with receptor expression – and these drugs are the backbone for many combo regimen programs in clinical development.

    Environment/perception shifts, new approaches to management, indication-based pricing or other novel pricing approaches, and innovative payment models may hold promise for controlling cost in this new era of combination therapy.

    Join ZS Associates for a live expert payer panel discussion on the challenges and potential solutions for managing the cost of combo oncology regimens. Topics will include:

    •Perspectives on oncology drug management and combination regimen pricing today
    •Potential payer-driven and pharma-driven solutions to price and cost management for oncology combo regimens
    •What oncology manufacturers should consider in engaging payers in the future

    The live payer webinar, co-moderated by Nicolle Hamilton, ZS Associates and Dominic Tyer, pharmaphorum, will take place on Wednesday, October 30 2019 from 14:00-15:15 GMT/10:00-11:15 ET.
  • Launch excellence in a disrupted world – challenges & opportunities Recorded: Sep 11 2019 70 mins
    Yasemin Karanis, Sarah Rickwood, Alexandra Smith, Markus Gores, IQVIA, Bill McClellan, IQVIA, Paul Tunnah, pharmaphorum

    The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care to specialty launch, but its future will be transformed even more radically.

    The advent of highly novel cell and gene therapies as well as prescription digital therapeutics is providing a serious set of forces for change in the market.

    Another comes from the challenges developed markets face, which renews the urgency for pharma companies to spread their launch successes beyond traditionally core markets.

    The pressures exerted by these forces require companies’ efforts in launch excellence to be able to ‘square the circle’ of better launch returns even as the launch environment becomes ever-more complex.

    To make sense of this landscape, this pharmaphorum webinar – in association with IQVIA – will look at the past, present and future of pharmaceutical launches. The event takes place on Wednesday 11th September from 11:00-12:00 BST.

    •Traditional launch approaches: In the past, launch was defined as being the first two years of a product’s existence on the market. This is still a crucial time for any product’s launch, however, in an increasingly multi-indicational world, for many products, launch is no longer a one-off event.

    •Current best practice in launch: Which launches have been the most commercially successful in recent years? By using IQVIA data the webinar will provide a unique view of the way in which commercial success has changed and look at what has driven the high-fliers.

    •Future of launch excellence. The nature of innovation is changing very rapidly, and with it, both what is defined as launch, and the key capabilities and resources required for excellent launches. IQVIA experts will outline how to prepare for the future of launch excellence.
  • Innovative contracting in Europe – a Trojan horse? Recorded: Sep 2 2019 64 mins
    Smita Sealey and Barry Farimond, ZS Associates, Malcolm Qualie, NHS England, Alain Boulanger, Filippo Drago

    With pricing of drugs at the centre of political and social debate, the market access and pricing environment in Europe has become increasingly challenging over the years. Innovative contracting has since become a common route to overcome these challenges and ensure timely access for patients.


    Join us on Monday 2nd September from 15:00-16:00 BST as we discuss the future of innovative contracting with our panel of European payers. Key topics to be covered include:

    To what extent and how contracting helps improve patient access?
    What prior successes and failures can teach us about designing contracts that deliver true value to the health systems?
    Can we avoid contracting and what would be the alternative?

    In the past decade, we have moved from simple discounting and traditional volume-based agreements to more complex value-based models involving measurement of health outcomes, risk-sharing and cost containment guarantees. The feasibility of these contracts tends to vary by EU market, dependent mainly on the available healthcare system infrastructure to collect and process data as well as other regulatory and philosophical differences.

    Ultimately, the question remains as to whether these agreements are a move towards better healthcare provision and more connected healthcare infrastructures, or are they slowing down access and creating administrative burden due to their complexity?
  • How pharma marketing can stay ahead of the evolving customer journey Recorded: Jul 23 2019 64 mins
    Robb DeFilippis, Managing Director, Life Sciences, Tag, Steve Pitts, Business Director, Tag, Dominic Tyer, pharmaphorum
    Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST.

    Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels?

    New developments in data and digital are changing traditional customer journeys and forcing pharmaceutical companies to evolve in order to keep up.

    Companies like Apple and Amazon have elevated customer expectations for personalised content and interactions across multiple channels, in the process setting new standards for marketing. But, as they push the envelope, what are the implications for pharma’s work in customer engagement?

    This pharmaphorum webinar, in association with Tag, will examine the challenges that pharma marketing faces to stay ahead of the evolving customer journey and offer expert insight from both the pharma and FMCG sectors on how to convert these challenges into opportunities .

    The expert panel will consider exclusive research carried out by Tag and pharmaphorum across the US, Europe and Asia-Pacific among senior decision-makers in pharma and FMCG marketing.

    The webinar, which takes place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST will also look at:
    •How pharma currently allocates its marketing budgets
    •Where marketers would like to have more money to invest
    •How much time is spent directing creative ideation and managing marketing production

    For more information, please visit:
  • Orphan medicines launch excellence: sustaining launch success Recorded: Jun 13 2019 72 mins
    Peter Meeus, European Orphan Medicines, Sarah Rickwood, IQVIA, Angela McFarlane, IQVIA, Paul Tunnah, pharmaphorum
    Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

    There are also a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in orphan drugs, as well as in digital technologies to support trials and treatment.

    But a new frontier of challenge faces orphan medicines companies as the gap between orphan medicines and mainstream specialty products narrows.

    To understand how to succeed in launching an orphan medicine in the coming years, companies must learn from past launches and apply an orphan medicines-focused launch excellence framework for success.

    This internationally relevant webinar will provide US and European examples to illustrate the ways in which the pharmaceutical market for orphan medicines is changing and how, consequently, launch strategies must evolve.

    This pharmaphorum debate, held in partnership with IQIVA, will also look at how pharmaceutical companies can optimise all the activities needed to take orphan medicines from clinical development to commercialisation, including:

    •Identifying the three fundamental challenges for orphan medicine launch excellence
    •Discussing the ways in which companies launching orphan medicines can learn from excellence in mainstream launches
    •Examining, in-depth, the specific areas of focus which are crucial for orphan medicines excellence.
  • Navigating new frontiers: Ways to find space in the future RA market Recorded: Mar 21 2019 52 mins
    Helen Parfitt, Head of Therapy Watch, Research Partnership, Mariel Metcalfe and Mark Hollis, Research Partnership
    Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).

    The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

    Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

    Analysis of Therapy Watch data, a real-time' syndicated market tracking tool from Research Partnership, shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

    This pharmaphorum webinar, held in conjunction with Research Partnership, will use the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

    This webinar will provide an opportunity to interact with the panel about how companies can best harness the potential of this increasingly complex, but highly rewarding, market.

    Topics to be covered include:

    The European RA market
    Current status and market situation of JAK inhibitors (key EU5 countries)
    Uptake curve of JAKs compared to other new entrants and biosimilars
    Profile of physicians prescribing JAKS
    Country differences
    The future of new classes of JAK inhibitors
  • Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal Recorded: Feb 7 2019 73 mins
    Erik Nordkamp, GM UK, Pfizer, Dr Keri Torney, Deputy Director Life Sciences, NHS England, Angela McFarlane, IQVIA
    Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS.

    With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.

    This pharmaphorum webinar, held in partnership with IQVIA, will analyse the current and future landscape for UK life sciences as well as what steps have been taken so far to boost the sector.

    Panellists from across the industry will look at the challenges presented by the current situation with Brexit and how the 10-Year Plan and the Sector Deal 2 (or 2018) play into this. They will discuss the positive steps taken by the government to prepare NHS innovation for a radically different future and make sure the UK remains an attractive location for ongoing inward investment from global pharma.

    Topics to be covered include:

    •Highlights of the 10-Year Plan and the second Sector Deal
    •Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019
    •The NHS innovation uptake agenda
    •Maintaining UK attractiveness for inward global pharma and biotech investment
  • Cancer, genomics and personalised medicine: Modelling the future of oncology Recorded: Jan 29 2019 61 mins
    Danyi Wen, Shanghai LIDE Biotech, Stefan Jellbauer, Mitra Biotech, Lakshmi Santhosh Maithel, Repositi
    The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one.

    The move towards immunotherapies heralds much promise and this is potentially just the beginning. As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible.
    To delve further into this pharmaphorum is pleased to present an exclusive online discussion.

    Bringing together experts at the cutting edge of this field it aims to interrogate where we are in terms of this shift towards personalised oncology, what this means in terms of the development pathway and looks at the approaches which could (and will) fully evolve the way that cancer treatments are developed in terms of efficacy, approach and outcome.

    this free to attend event will cover a number of topics critical to the future of oncology including:
    •The changing face of cancer: how do we define it now?
    •Personalised medicine in practice – where are we now in cancer?
    •What are the implications from these changes for clinical trials?
    •How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run
    •What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
    •Modelling for the future of cancer – can this be done for personalised therapies?
  • Metrics to meaning: demonstrating the value of medical communications Recorded: Jan 23 2019 62 mins
    Scott McGregor, Allergan, Lynda Chang, Complete HealthVizion, David Pearce, Complete HealthVizion, Dominic Tyer, pharmaphorum
    Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical communications activities they undertake.

    Naturally, there are a huge number of metrics that could be used to measure and demonstrate medical communications value. The challenge is to identify, and track, those metrics that really matter, and ensure this information is interpreted effectively.

    This pharmaphorum webinar, which will be held in partnership with Complete HealthVizion, will look at how to measure medical communications activities, how to continue with what is successful and how to change what isn’t working.

    This means identifying what can be measured, both in terms of reach and engagement as well as behavioural impact, deciding what ‘great’ looks like and how best to define success.

    The expert panel will also look at how behavioural science can provide a framework to develop smarter communications and, ultimately, drive better patient outcomes.

    This Metrics to Meaning webinar will take place on Wednesday, 23rd January, at 15:00 pm GMT (10:00 EST) and will teach you how to measure the effectiveness of different types of medical communications programmes.

    Interacting with the panel will also allow you to learn about a range of practical approaches to implementing metrics, including:

    • Innovative ways to measure medical communications value and success
    • How to help medical affairs and publications teams demonstrate greater value
    • How to optimise tactical outputs year on year
    • The importance of demonstrating and measuring behavioural change

    In doing so they will also discuss the role of behaviour and the implications of this for measuring success.
  • The devil’s in the e-detail: what HCPs really want from you Recorded: Dec 6 2018 68 mins
    Heiko Schmidt, Integrated Multichannel Marketing and Sales, Bayer, Sari Ruth Carter, Head of Marketing, Anthill Agency
    Communication; we all do it, it is a critical part of effective business practice and in this pharma is no exception.

    It is no secret that for pharma companies, face time with healthcare professionals (HCPs) has reduced drastically over the last 10 years while the cost of in person engagements has increased significantly.

    Like any customer their expectations for the content they receive have changed, with a focus on useful, succinct and easy to consume materials rather than the sales materials of old.

    So what is it that HCPs want and through this lens, what is it that pharma should be doing?

    The evidence points towards creating meaningful two-way conversations through multiple channels, connecting otherwise siloed touchpoints with and for HCPs in the process.

    For the past 40 years detailing has been the backbone of pharma/HCP communication – but what about e-Detailing? Is it just detailing on an ipad or is it supposed to be something more? How does this fit and what is possible, and more importantly desirable?

    To analyse the current situation and present practical insights, pharmaphorum presents a new free to attend digital debate. Working with our partner Anthill agency we have put together a panel of leading experts from Bayer and Anthill.

    This debate will cover:

    •What is the current landscape for optimal HCP communication?
    •What is the future in terms of HCP channel preference?
    •New technologies in pharma marketing that help you to better engage with HCPs and extend HCP reach – AI, chatbots, self-detailing
    •How to reach more HCPs, when, where and how they want
    •How to overcome low content usage by HCPs
    •The most common challenges for traditional eDetailing effectiveness
    •How to achieve better communication without having to reinvent the wheel
    •How to activate your existing content and reach all customers willing to engage with your brand, regardless of their preference.
  • Can simulated datasets unlock the potential of patient data? Recorded: Nov 27 2018 68 mins
    Jem Rashbass, Health Data Insight, Chris Carrigan, use MY data, Adam Reich, IQVIA, Dominic Tyer, pharmaphorum
    Patient level data offers the promise of insights which can craft new and better pathways, enable development of innovative therapies and treatments, and of course identify and prevent diseases much earlier in their lifecycle.

    One area of particular interest is cancer. However, in trying to realise the potential, the health sector is faced with the conundrum of protecting patients’ identities, while at the same time allowing doctors access to their data and enabling industry to benefit from vital insights into the disease.

    This presents a paradox, as the UK has some of the best healthcare data in the world, however, accessing the data can be challenging and time consuming due to patient confidentiality checks.

    So, what is the solution?

    IQVIA brings a unique perspective to this event, having partnered with Health Data Insight to develop an innovative solution to this seemingly intractable problem: Simulacrum, a database comprised of only artificial data that is modelled on real patient data collected by the National Cancer Registration and Analysis Service (NCRAS) in England.

    Simulacrum has already produced identical results to the real data when predicting incidence of tumours in the population, whilst simultaneously removing any risk of breaching patient confidentiality.

    In this webinar, IQVIA and pharmaphorum will also provide advice to industry, patient advocacy groups and healthcare professionals on how to leverage Simulacrum, and utilise this simulated dataset to facilitate access to England’s world-leading healthcare data, while complying with regulations designed to protect and maintain individual confidentiality.
  • Digital therapeutics and healthcare innovation Recorded: Oct 12 2018 70 mins
    Roberto Ascione, Healthware International, Megan Coder, Digital Therapeutics Alliance, Pierre Leurent, Voluntis
    Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patient care.

    The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.

    At the same time as digital therapeutics are breaking new ground there’s a whole ecosystem of digital health innovations that are also tackling healthcare issues in new and imaginative ways.

    From doctor-patient communication to managing healthcare costs, from healthcare monitoring to clinician workflow, the range of digital health tools and services available is rapidly expanding.

    We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.

    This free webinar will also see our expert panel:
    •Consider the current state of play with digital therapeutics and what the future holds for them
    •Discuss how to harness healthcare innovations to involve and engage patients
  • Engaging with patient communities – tailoring approaches Recorded: Oct 11 2018 62 mins
    Jamie Bearse, Thomas Farrington, Chuck Strand and Jenny Kite
    Change Together will be presenting a live webinar with leading figures from the patient advocacy community, who will discuss communication and engagement as well as the different approaches advocacy groups can take to address the unique challenges of their communities. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.
  • Realising the biotech promise: addressing the path to market Recorded: Oct 9 2018 72 mins
    Steve Bates, BIA, Sheela Upadhyaya, NICE, Fred Jacobs, TYG, Dean Summerfield, IQVIA
    Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

    The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

    These companies have to navigate a rapidly changing and increasingly complex landscape from pre-clinical valuation through foresight and planning at every stage of the asset life cycle - and at a time when Brexit adds uncertainty about regulatory approval and launch windows.

    Working with IQVIA, pharmaphorum has assembled a specialist panel to discuss these challenges and the most effective routes to overcoming them.

    On Tuesday 9th October at 15:00 BST / 10:00 EST we will present a free-to-attend online debate which will bring these experts together to deliver insight on topics such as market valuation, financing, navigating regulatory hurdles, patient engagement & HTA strategies through to successful commercialisation.
  • Engaging with HCPS: what do HCPs want from medical meetings? Recorded: Jun 26 2018 65 mins
    Aoife Delmas, European Society of Cardiology, Katie Koziol and Andrew Moore, Ashfield Meetings & Events
    There has been a myriad of reasons over the past few years to safely assume the popularity and perceived worth of face-to-face medical meetings was well and truly on the decline – from advances in technology, to funding challenges.

    Separate, yet complementary studies looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Yet a 2018 study by Ashfield looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Furthermore, HCPs exhibit consumer behaviours in selecting and attending events – which means that while these conferences offer potential engagement riches, they have to offer a specific mix of focus, value and ROI to be successful. To analyse this situation, discuss the learnings from the research and offer guidance on what a modern medical meeting needs to be we present an exclusive debate.

    Bringing together experts from Ashfield Meetings & Events and the European Society of Cardiology our panel will discuss:

    1. Findings from the 2018 Ashfield Science of HCP Meetings research and whitepaper
    2. How HCPs want to engage with pharma and scientific communications
    3. What works? How to create the events that HCPs want to attend
    4. The future of meetings - balancing face to face and digital
    5. How HCPs determine whether a meeting is likely to be worth the investment
    6. Strategies and tactics for planners and meeting stakeholders to implement to continue to add value for HCPs attending medical meetings
  • How to make digital work in medtech Recorded: Jun 21 2018 71 mins
    Bryn Davies (Critical Insights), Lars U. Diemer (Agnitio), Markus Ott (Ascensia), Jerome d'Astros (Edwards Lifesciences)
    The rise of mobile devices and apps, not to mention the involvement of non-medical technology players, is creating a wave of irrevocable digital change for medtech.
    It’s transforming how the sector reaches and engages with its stakeholders and customers, and in doing so provides vital opportunities to reshape a company’s commercial model.
    But although the sector can lay claim to some key success stories with digital technology, there remain a number of roadblocks impeding real digital progress for medtech.

    In this webinar we will discuss key digital lessons for medtech from other healthcare sectors, steps to take for a successful digital transformation and how to ensure ROI from digital technology.
    The free webinar will also see our expert panel:
    •Explore the practical impacts of the new medtech business model
    •Re-think the customer experience for payers and HCPs
    •Learn how digital technology enables you to deliver more customer value – while powering commercial success
    •Find out how virtual engagement technologies can make it happen
    •See best practices and use cases from your peers
  • Using education and awareness to drive positive change for patients Recorded: May 3 2018 63 mins
    Gwen Nichols (LLS), Kathleen Weis (AAMDSIF), Brian Tomlinson (CancerCare), Gary Nolan (Know AML), Jenny Kite (Astellas)
    Change Together will be presenting a live webinar with leading figures from the patient advocacy community, who will debate how we can drive positive change for patients through improved education and awareness. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.
    The panel and the topics they will be covering are as follows.
    • Dr. Gwen Nichols, Chief Medical Officer of the Leukemia & Lymphoma Society on coordinating the group’s groundbreaking Beat AML Master Trial, which is taking the latest research from the lab to the clinic.
    • Kathleen Weis, Chief Executive Officer of the Aplastic Anemia and MDS International Foundation, on the changing treatment landscape, which is bringing new hope to patients, and how her group is supporting the AML community.
    • Representatives from Know AML, the global AML awareness initiative established in 2017 – Gary Nolan from the Know AML secretariat and Brian Tomlinson, patient advocate committee member and Chief Program Officer at CancerCare – explaining how the project started and the role that patient advocates play in it.
  • Digital health: how can technology be used to engage hard-to-reach patients? Recorded: Apr 20 2018 65 mins
    Trishna Bharadia, MS patient advocate, Jo Sopala, MS Trust, Rachel Morrison, NHS Western Isles
    Helping someone live with a condition as complex as MS can be fraught with challenges.

    MS professionals are asked to manage multiple physical and psychological symptoms while following complicated drug monitoring regimes, all in the face of shirking resources and growing caseloads.

    As the burden of monitoring people on disease modifying therapies has grown, a corresponding lack of resource for symptom management has led to inequity of services for those with progressive disease.
    Across the UK, however, technology is being used to overcome these obstacles, by erasing geographic boundaries and expanding access.

    From conducting video consultations to setting up online peer support groups, digital health can and is being utilised to improve services for everyone.

    As part of the Quality in the Delivery of Services (QuDoS) in MS recognition programme, a panel of experts will discuss how to meet the information, support and engagement needs of people living with MS through technology.

    The live webinar, produced by pharmaphorum with the support of the MS Trust and Biogen, will feature the views of patients and professionals alike.

    The panel, which will include Jo Sopala, Director of Development at the MS Trust, will discuss using digital health to:
    -Increase patient access to quality, trusted information through digital translation services
    -Offer greater support through online peer support and symptom management apps
    -Boost adherence through electronic reminder systems
    -Increase involvement in clinical trials through wearable technologies
    -Increase access to services through remote appointments
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: How to make digital work in medtech
  • Live at: Jun 21 2018 11:00 am
  • Presented by: Bryn Davies (Critical Insights), Lars U. Diemer (Agnitio), Markus Ott (Ascensia), Jerome d'Astros (Edwards Lifesciences)
  • From:
Your email has been sent.
or close